Tata Institute Big Success: developed cancer ablet for just Rs 100
Researchers at the Tata Memorial Center (TMC) worked diligently for ten years to create a tablet that they claimed could not only prevent cancer from returning but also reduce the side effects of treatments like radiation and chemotherapy by 50%.
In a major breakthrough, Mumbai’s Tata Institute claims to have developed a breakthrough treatment that prevents cancer from recurring. Tata Institute Big Success: developed Cancer Tablet for Just Rs 100. Researchers at the Tata Memorial Center (TMC) worked diligently for ten years to create a tablet that they claimed could not only prevent cancer from returning but also reduce the side effects of treatments like radiation and chemotherapy by 50%.
Speakig to media Rajendra Badve, senior cancer surgeon at Datata Memorial Hospital and part of the research group, explained the process behind the discovery. He said, “Human cancer cells injected into mice formed tumors. Mice underwent radiation therapy, chemotherapy and surgery.
Dying cancer cells have been observed to release chromatin particles, which, when they enter healthy cells, turn them into cancer.” Researchers have found a solution to this problem by giving rats pro-oxidant tablets of resveratrol and copper (R+Cu).
Dabadave explained, “R+Q tablets produce oxygen radicals that destroy chromatin particles. When taken orally, they produce oxygen radicals in the stomach, which are quickly absorbed into the bloodstream. These radicals destroy circulating chromatin particles, preventing metastasis – the movement of cancer cells from one part of the body to another.
Also Read: CBSE Class 10th Result 2024 Will Announce On This Date: Download Cbseresults.Nic.In
Tablet Prevents Chemotherapy Toxicity.” Referred to as the “Magic of R+Cu” in their presentation, the tablet significantly reduced the side effects of cancer treatment by 50% and demonstrated nearly 30% effectiveness in preventing cancer recurrence.
Researchers claim its effectiveness on various cancers affecting the pancreas, lung and oral regions. After nearly a decade of dedicated work by Tata doctors, the tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). tIFR scientists have applied for approval and once granted, the tablet is expected to hit the market by June-July.
Also Read: Bank Holidays: Bank Will Closed For 14 Days In March 2024
This affordable tablet priced at Rs 100 is poised to revolutionize cancer treatment,” highlighted Dr Badve. While human trials for the prevention are still pending and are expected to take about five years to complete, the positive effect on side effects has been tested in mice and humans. Dabyadwe acknowledged initial skepticism in the research process but emphasized the enormous success achieved, saying, “It was a huge success.”
Comments are closed.